October 14, 2024
1 min watch
Save
VIDEO: Pros, cons of complement inhibitors for geographic atrophy considered
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Barbara Blodi, MD, discusses advancements in complement inhibition treatments for geographic atrophy.
At the ASRS annual meeting, there were panel discussions about the pros and cons of these types of therapies, Blodi said.
The complement inhibitors pegcetacoplan and avacincaptad pegol were approved by the FDA for the treatment of geographic atrophy in 2023.
“We’re really at the beginning of understanding how these complement inhibition drugs work, and I think there’s still room for improvement,” Blodi said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Blodi reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.